More

Building Block Catalogue

225 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

14 Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from September 2020

Recent News

  • 24 September 2020   Press Releases

    Enamine is selected for Horizon 2020 global project “AIDD” ...

    Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München,Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.

    Read press release
  • 17 September 2020   Press Releases

    Enamine Ltd. Released Coronavirus Library to Support COVID-19 Research ...

    Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), today announced the release of the Coronavirus Library. The new screening library capitalizes on Enamine’s decades of chemical R&D, advanced library design expertise, and experience with creating focused antiviral libraries. Enamine is a participant of a global Open Science initiative “COVID Moonshot”, aimed at discovering novel therapeutics against SARS-CoV-2.

    Read press release

  • 15 April 2020   Press Releases

    Enamine and Chemspace collaborate with Blue Dolphin Lead ...

    Today Enamine, a leading provider of small molecules and drug discovery services, Chemspace, an online catalog with the largest offer of small molecules to search and buy, and Blue Dolphin Lead Discovery, a research organization focused on a fee-for-service virtual screening, announced the launch of the collaboration to support drug discovery projects.

    Read press release

Upcoming events

Ro3 Fragment Library

General set of Ro3 compliant molecules for cherry-picking

[Ro3-F][/Ro3-F] compounds

Enamine’s design and synthesis capabilities allow the addition of more than 140 000 new organic compounds to its catalogue each year. Fast growth and permanent enhancement of our Building Block Collection with novel, top level synthetic chemistry molecules resulted in the world largest set of high quality fragments.

Enamine Ro3 Fragments comprise a remarkable number of new scaffolds and unique chemotypes within the widest range of molecular frameworks. The library does not include covalent modifiers and toxicophores, all industry affiliated exclusion filters and MedChem refinements have been applied.

Key features

  • [Ro3-F][/Ro3-F] molecules out of 2 725 753 Collection
  • Ro3 compliance – 100%, Heavy atoms 9…19
  • MedChem inspection & Chemotype control
  • Sensible Diversity – 32% mean Tanimoto distance (ECFP4)

Key benefits

The hits discovered from our fragments are expected to yield lead compounds fast and easily. Follow-up investigation can be readily performed with analogues available from stock, REAL database in one stage conversion or derived from new MedChem-driven synthesis. All required intermediates, core building blocks and decorating reagents are available from Enamine stock Collection.

Examples of the molecules in the library

FOLLOW US